Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Sarcoma | 43 | 2023 | 1888 | 5.940 |
Why?
|
Retroperitoneal Neoplasms | 18 | 2022 | 341 | 5.220 |
Why?
|
Extremities | 15 | 2023 | 857 | 2.600 |
Why?
|
Liposarcoma | 8 | 2023 | 323 | 2.050 |
Why?
|
Soft Tissue Neoplasms | 11 | 2023 | 1356 | 1.830 |
Why?
|
Mesothelioma | 12 | 2015 | 814 | 1.670 |
Why?
|
Pleural Neoplasms | 11 | 2015 | 604 | 1.630 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 37 | 2023 | 5088 | 1.470 |
Why?
|
Neoplasm Recurrence, Local | 30 | 2023 | 8896 | 1.400 |
Why?
|
Lung Neoplasms | 49 | 2023 | 12874 | 1.350 |
Why?
|
Radiotherapy, Adjuvant | 21 | 2021 | 1761 | 1.270 |
Why?
|
Tumor Burden | 10 | 2020 | 1892 | 1.170 |
Why?
|
Organs at Risk | 3 | 2015 | 350 | 1.010 |
Why?
|
Pneumonectomy | 12 | 2018 | 1083 | 1.000 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 39 | 2023 | 11303 | 0.970 |
Why?
|
Radiation Oncology | 4 | 2021 | 542 | 0.900 |
Why?
|
Hemangiosarcoma | 4 | 2020 | 227 | 0.850 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 4 | 2021 | 1604 | 0.690 |
Why?
|
Radiotherapy Dosage | 13 | 2021 | 2885 | 0.680 |
Why?
|
Preoperative Care | 5 | 2021 | 2265 | 0.630 |
Why?
|
Neoplasm, Residual | 4 | 2017 | 965 | 0.610 |
Why?
|
Combined Modality Therapy | 26 | 2022 | 8577 | 0.600 |
Why?
|
Radiation Pneumonitis | 4 | 2017 | 104 | 0.600 |
Why?
|
Survival Rate | 36 | 2020 | 12795 | 0.590 |
Why?
|
Radiotherapy, Intensity-Modulated | 6 | 2017 | 807 | 0.590 |
Why?
|
Radiotherapy | 6 | 2021 | 1536 | 0.570 |
Why?
|
Neoadjuvant Therapy | 9 | 2021 | 2618 | 0.570 |
Why?
|
Cerebellar Neoplasms | 1 | 2019 | 588 | 0.500 |
Why?
|
Medulloblastoma | 1 | 2019 | 702 | 0.480 |
Why?
|
Disease-Free Survival | 18 | 2020 | 6881 | 0.470 |
Why?
|
Fibrosarcoma | 2 | 2017 | 342 | 0.460 |
Why?
|
Vinblastine | 11 | 2013 | 499 | 0.460 |
Why?
|
Models, Economic | 1 | 2017 | 713 | 0.450 |
Why?
|
Genital Neoplasms, Male | 1 | 2013 | 74 | 0.450 |
Why?
|
Neoplasm Staging | 36 | 2021 | 10926 | 0.450 |
Why?
|
Thyroglobulin | 1 | 2012 | 114 | 0.440 |
Why?
|
Liposarcoma, Myxoid | 2 | 2023 | 64 | 0.430 |
Why?
|
Brachytherapy | 3 | 2014 | 1244 | 0.420 |
Why?
|
Middle Aged | 103 | 2021 | 212155 | 0.400 |
Why?
|
Aged | 90 | 2021 | 161379 | 0.400 |
Why?
|
Adult | 90 | 2023 | 211523 | 0.380 |
Why?
|
Aged, 80 and over | 42 | 2020 | 57615 | 0.380 |
Why?
|
Radiosurgery | 5 | 2018 | 1266 | 0.370 |
Why?
|
Prognosis | 30 | 2021 | 28718 | 0.370 |
Why?
|
Humans | 157 | 2023 | 725001 | 0.370 |
Why?
|
Epirubicin | 11 | 2006 | 80 | 0.360 |
Why?
|
Solitary Fibrous Tumors | 2 | 2020 | 74 | 0.350 |
Why?
|
Upper Extremity | 2 | 2012 | 610 | 0.350 |
Why?
|
Chemotherapy, Adjuvant | 14 | 2018 | 3449 | 0.340 |
Why?
|
Carcinoma, Small Cell | 4 | 2006 | 417 | 0.340 |
Why?
|
Neoplasms, Multiple Primary | 1 | 2013 | 606 | 0.340 |
Why?
|
Lymph Nodes | 2 | 2020 | 3428 | 0.340 |
Why?
|
Kaplan-Meier Estimate | 10 | 2019 | 6527 | 0.330 |
Why?
|
Carcinoma, Papillary | 2 | 2015 | 782 | 0.320 |
Why?
|
Neck | 1 | 2012 | 686 | 0.320 |
Why?
|
Gastrointestinal Diseases | 2 | 2015 | 1151 | 0.310 |
Why?
|
Biopsy, Fine-Needle | 1 | 2012 | 1073 | 0.310 |
Why?
|
Female | 111 | 2021 | 375303 | 0.300 |
Why?
|
Peritoneal Cavity | 2 | 2015 | 151 | 0.300 |
Why?
|
Breast Neoplasms | 22 | 2021 | 20448 | 0.300 |
Why?
|
Cisplatin | 16 | 2013 | 1622 | 0.300 |
Why?
|
Treatment Outcome | 37 | 2023 | 61674 | 0.280 |
Why?
|
Follow-Up Studies | 28 | 2020 | 38720 | 0.280 |
Why?
|
Radiation Dosage | 7 | 2021 | 1917 | 0.270 |
Why?
|
Ifosfamide | 9 | 2013 | 226 | 0.270 |
Why?
|
Rare Diseases | 1 | 2010 | 547 | 0.270 |
Why?
|
Thyroid Neoplasms | 3 | 2015 | 2227 | 0.270 |
Why?
|
Male | 86 | 2021 | 346964 | 0.270 |
Why?
|
Retrospective Studies | 47 | 2023 | 74145 | 0.250 |
Why?
|
Cost-Benefit Analysis | 1 | 2017 | 5342 | 0.250 |
Why?
|
Cone-Beam Computed Tomography | 2 | 2020 | 422 | 0.250 |
Why?
|
Survival Analysis | 18 | 2017 | 10244 | 0.240 |
Why?
|
Deoxycytidine | 4 | 2013 | 817 | 0.230 |
Why?
|
Treatment Failure | 6 | 2015 | 2613 | 0.230 |
Why?
|
Skin Neoplasms | 2 | 2020 | 5480 | 0.220 |
Why?
|
Consensus | 5 | 2022 | 2821 | 0.220 |
Why?
|
Small Cell Lung Carcinoma | 2 | 2020 | 368 | 0.220 |
Why?
|
Postoperative Complications | 6 | 2020 | 15004 | 0.210 |
Why?
|
Neoplasms, Radiation-Induced | 2 | 2019 | 549 | 0.210 |
Why?
|
Leiomyosarcoma | 3 | 2019 | 457 | 0.200 |
Why?
|
Bone Neoplasms | 4 | 2016 | 2512 | 0.200 |
Why?
|
Practice Guidelines as Topic | 2 | 2015 | 7256 | 0.200 |
Why?
|
Hemangioendothelioma, Epithelioid | 1 | 2021 | 54 | 0.190 |
Why?
|
Observer Variation | 3 | 2016 | 2608 | 0.190 |
Why?
|
Not-For-Profit Insurance Plans | 1 | 2020 | 2 | 0.190 |
Why?
|
United States Department of Defense | 1 | 2020 | 31 | 0.190 |
Why?
|
Postoperative Care | 2 | 2019 | 1487 | 0.190 |
Why?
|
Hemangiopericytoma | 1 | 2020 | 77 | 0.190 |
Why?
|
Neuroectodermal Tumors | 1 | 1999 | 27 | 0.180 |
Why?
|
Paclitaxel | 8 | 2021 | 1685 | 0.170 |
Why?
|
Fibromatosis, Aggressive | 2 | 2016 | 111 | 0.170 |
Why?
|
Heart Diseases | 3 | 2021 | 2761 | 0.170 |
Why?
|
Liver Transplantation | 6 | 1999 | 2159 | 0.160 |
Why?
|
Diethylstilbestrol | 2 | 1997 | 93 | 0.160 |
Why?
|
Fibrin Fibrinogen Degradation Products | 2 | 2011 | 428 | 0.160 |
Why?
|
Colon | 2 | 2017 | 1770 | 0.160 |
Why?
|
Collagen Diseases | 1 | 2017 | 36 | 0.160 |
Why?
|
Young Adult | 11 | 2020 | 55791 | 0.160 |
Why?
|
Scalp | 1 | 2020 | 370 | 0.150 |
Why?
|
Floxuridine | 1 | 1996 | 50 | 0.150 |
Why?
|
Proportional Hazards Models | 7 | 2022 | 12318 | 0.150 |
Why?
|
Predictive Value of Tests | 10 | 2016 | 14955 | 0.150 |
Why?
|
Analysis of Variance | 5 | 2020 | 6396 | 0.150 |
Why?
|
Granulocyte Colony-Stimulating Factor | 4 | 1997 | 638 | 0.150 |
Why?
|
Neoplasm Metastasis | 11 | 2019 | 4887 | 0.140 |
Why?
|
Thyroidectomy | 2 | 2012 | 877 | 0.140 |
Why?
|
Cancer Vaccines | 1 | 2023 | 1009 | 0.140 |
Why?
|
Infarction | 1 | 2017 | 226 | 0.140 |
Why?
|
Hepatectomy | 2 | 2015 | 557 | 0.130 |
Why?
|
Receptors, Progesterone | 2 | 2019 | 1096 | 0.130 |
Why?
|
Tomography, X-Ray Computed | 7 | 2016 | 19903 | 0.130 |
Why?
|
Adrenal Glands | 1 | 2017 | 545 | 0.130 |
Why?
|
Sumoylation | 1 | 2015 | 87 | 0.130 |
Why?
|
Salvage Therapy | 2 | 2018 | 1250 | 0.120 |
Why?
|
Fluorouracil | 8 | 2003 | 1626 | 0.120 |
Why?
|
Cyclophosphamide | 10 | 2003 | 2205 | 0.120 |
Why?
|
Fractures, Spontaneous | 1 | 2016 | 227 | 0.120 |
Why?
|
Risk Factors | 17 | 2019 | 70971 | 0.120 |
Why?
|
Astrocytoma | 1 | 2018 | 783 | 0.120 |
Why?
|
Lower Extremity | 2 | 2012 | 1092 | 0.120 |
Why?
|
Biological Products | 1 | 2022 | 815 | 0.120 |
Why?
|
Antineoplastic Agents, Hormonal | 2 | 2003 | 1512 | 0.120 |
Why?
|
Lymphatic Metastasis | 5 | 2017 | 2901 | 0.120 |
Why?
|
Drainage | 1 | 1999 | 1124 | 0.110 |
Why?
|
Nephrectomy | 2 | 2017 | 1033 | 0.110 |
Why?
|
Magnetic Resonance Imaging | 5 | 2023 | 34755 | 0.110 |
Why?
|
Drug Administration Schedule | 7 | 2007 | 4939 | 0.110 |
Why?
|
Thoracic Surgical Procedures | 2 | 2013 | 335 | 0.110 |
Why?
|
Coronary Vessels | 2 | 2021 | 3014 | 0.110 |
Why?
|
Necrosis | 1 | 2017 | 1624 | 0.110 |
Why?
|
Limb Salvage | 2 | 2015 | 413 | 0.110 |
Why?
|
Receptors, Estrogen | 3 | 2019 | 2167 | 0.110 |
Why?
|
Lymph Node Excision | 2 | 2012 | 1220 | 0.110 |
Why?
|
Gene Expression Regulation, Neoplastic | 3 | 2019 | 8453 | 0.110 |
Why?
|
Thoracic Wall | 1 | 2014 | 197 | 0.110 |
Why?
|
Duodenum | 1 | 2015 | 469 | 0.110 |
Why?
|
Asbestos | 1 | 2013 | 249 | 0.100 |
Why?
|
Radiation Injuries | 1 | 2019 | 1165 | 0.100 |
Why?
|
Meningeal Neoplasms | 1 | 2020 | 1208 | 0.100 |
Why?
|
Carcinogens | 1 | 2013 | 467 | 0.100 |
Why?
|
Heart | 3 | 2021 | 4367 | 0.100 |
Why?
|
Iodine Radioisotopes | 1 | 2014 | 1031 | 0.100 |
Why?
|
Quality-Adjusted Life Years | 1 | 2017 | 1656 | 0.100 |
Why?
|
Myoglobin | 1 | 2011 | 154 | 0.100 |
Why?
|
Stomach | 1 | 2015 | 683 | 0.100 |
Why?
|
Tamoxifen | 2 | 2007 | 985 | 0.100 |
Why?
|
Antineoplastic Agents, Phytogenic | 5 | 1997 | 623 | 0.100 |
Why?
|
Skull Neoplasms | 1 | 2011 | 172 | 0.100 |
Why?
|
Brain Neoplasms | 5 | 2018 | 8644 | 0.090 |
Why?
|
Neoplasms, Second Primary | 2 | 2012 | 1023 | 0.090 |
Why?
|
Creatine Kinase, MB Form | 1 | 2011 | 215 | 0.090 |
Why?
|
Endonucleases | 1 | 2013 | 380 | 0.090 |
Why?
|
Time Factors | 11 | 2017 | 40178 | 0.090 |
Why?
|
Fibrosis | 1 | 2017 | 1991 | 0.090 |
Why?
|
Hyperthermia, Induced | 1 | 2013 | 367 | 0.090 |
Why?
|
Connective Tissue | 2 | 2022 | 418 | 0.090 |
Why?
|
Radiography | 3 | 2015 | 6949 | 0.090 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 3 | 2003 | 903 | 0.090 |
Why?
|
Receptor, erbB-2 | 1 | 2019 | 2334 | 0.090 |
Why?
|
Dura Mater | 1 | 2011 | 286 | 0.090 |
Why?
|
Chest Pain | 2 | 2014 | 1102 | 0.090 |
Why?
|
Confidence Intervals | 3 | 2007 | 2976 | 0.090 |
Why?
|
Vascular Diseases | 1 | 2017 | 1142 | 0.090 |
Why?
|
Intraoperative Care | 1 | 2013 | 761 | 0.090 |
Why?
|
ras Proteins | 1 | 2014 | 1075 | 0.090 |
Why?
|
Incidence | 10 | 2021 | 20743 | 0.080 |
Why?
|
Edema | 1 | 2013 | 770 | 0.080 |
Why?
|
Adolescent | 12 | 2017 | 84411 | 0.080 |
Why?
|
Intestine, Small | 1 | 2015 | 1213 | 0.080 |
Why?
|
Heart Neoplasms | 1 | 2012 | 378 | 0.080 |
Why?
|
Population Surveillance | 1 | 2019 | 2645 | 0.080 |
Why?
|
Immunotherapy | 2 | 2023 | 4257 | 0.080 |
Why?
|
Clinical Trials as Topic | 2 | 2020 | 7835 | 0.080 |
Why?
|
Algorithms | 4 | 2015 | 13759 | 0.080 |
Why?
|
Digestive System Surgical Procedures | 1 | 2013 | 567 | 0.080 |
Why?
|
Neutropenia | 6 | 1998 | 879 | 0.080 |
Why?
|
Disease Progression | 5 | 2020 | 13161 | 0.080 |
Why?
|
Smoking | 4 | 2013 | 8882 | 0.080 |
Why?
|
Dose-Response Relationship, Drug | 6 | 2007 | 10968 | 0.080 |
Why?
|
Women's Health | 1 | 1997 | 1992 | 0.080 |
Why?
|
Methotrexate | 6 | 2003 | 1707 | 0.080 |
Why?
|
Antineoplastic Agents | 6 | 2013 | 13563 | 0.080 |
Why?
|
Skin Transplantation | 1 | 2012 | 1085 | 0.080 |
Why?
|
Etoposide | 3 | 2006 | 638 | 0.070 |
Why?
|
Neoplasm Proteins | 2 | 2015 | 3708 | 0.070 |
Why?
|
Cell Survival | 1 | 2017 | 5908 | 0.070 |
Why?
|
Troponin I | 1 | 2011 | 603 | 0.070 |
Why?
|
Injections, Intravenous | 3 | 2006 | 1440 | 0.070 |
Why?
|
Cohort Studies | 7 | 2021 | 39883 | 0.070 |
Why?
|
BRCA1 Protein | 1 | 2013 | 1115 | 0.070 |
Why?
|
Radiation Tolerance | 1 | 2009 | 488 | 0.070 |
Why?
|
Patient Acceptance of Health Care | 1 | 2020 | 2957 | 0.070 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 2013 | 1384 | 0.070 |
Why?
|
Diagnostic Imaging | 2 | 2021 | 3461 | 0.070 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2021 | 3169 | 0.070 |
Why?
|
Carcinoma | 2 | 2015 | 2337 | 0.070 |
Why?
|
Rhabdomyosarcoma | 2 | 2016 | 381 | 0.070 |
Why?
|
Vascular Neoplasms | 1 | 2007 | 177 | 0.070 |
Why?
|
Hodgkin Disease | 1 | 2013 | 1410 | 0.070 |
Why?
|
Radiotherapy, Conformal | 2 | 2020 | 545 | 0.070 |
Why?
|
Methylprednisolone | 3 | 1999 | 387 | 0.070 |
Why?
|
Early Detection of Cancer | 1 | 2019 | 2958 | 0.070 |
Why?
|
Diabetes Complications | 1 | 2012 | 1352 | 0.070 |
Why?
|
Proto-Oncogene Proteins | 2 | 2014 | 4561 | 0.070 |
Why?
|
Neoplasm Invasiveness | 4 | 2017 | 3601 | 0.070 |
Why?
|
Sensitivity and Specificity | 4 | 2016 | 14713 | 0.070 |
Why?
|
Acute Disease | 1 | 2015 | 7090 | 0.070 |
Why?
|
Guanine | 1 | 2006 | 278 | 0.070 |
Why?
|
Aortic Aneurysm | 1 | 2010 | 654 | 0.060 |
Why?
|
Glutamates | 1 | 2006 | 394 | 0.060 |
Why?
|
Carcinoma, Merkel Cell | 1 | 2008 | 287 | 0.060 |
Why?
|
Risk Assessment | 3 | 2023 | 23178 | 0.060 |
Why?
|
Boston | 2 | 2015 | 9287 | 0.060 |
Why?
|
Healthcare Disparities | 1 | 2020 | 3065 | 0.060 |
Why?
|
Ultrasonography, Interventional | 1 | 2012 | 1468 | 0.060 |
Why?
|
Vena Cava, Inferior | 1 | 2007 | 433 | 0.060 |
Why?
|
Surgical Flaps | 1 | 2012 | 1613 | 0.060 |
Why?
|
Heart Failure | 3 | 2021 | 10378 | 0.060 |
Why?
|
Maximum Tolerated Dose | 1 | 2006 | 892 | 0.060 |
Why?
|
Venous Thromboembolism | 1 | 2016 | 1593 | 0.060 |
Why?
|
Patient Care Team | 1 | 2015 | 2541 | 0.060 |
Why?
|
Decision Making | 1 | 2017 | 3837 | 0.060 |
Why?
|
Prospective Studies | 8 | 2022 | 51853 | 0.060 |
Why?
|
HLA-A2 Antigen | 1 | 2023 | 213 | 0.060 |
Why?
|
Filgrastim | 3 | 1997 | 131 | 0.060 |
Why?
|
Infusions, Intravenous | 2 | 2006 | 2259 | 0.060 |
Why?
|
Sentinel Lymph Node Biopsy | 1 | 2007 | 679 | 0.060 |
Why?
|
Natriuretic Peptide, Brain | 1 | 2011 | 1535 | 0.060 |
Why?
|
Point-of-Care Systems | 1 | 2011 | 1137 | 0.050 |
Why?
|
Medical Oncology | 2 | 2021 | 2162 | 0.050 |
Why?
|
Kidney | 1 | 2017 | 7022 | 0.050 |
Why?
|
Retroperitoneal Space | 1 | 2022 | 165 | 0.050 |
Why?
|
Palliative Care | 2 | 2009 | 3359 | 0.050 |
Why?
|
Wound Healing | 1 | 2012 | 2769 | 0.050 |
Why?
|
Head and Neck Neoplasms | 2 | 2020 | 2671 | 0.050 |
Why?
|
Age Factors | 5 | 2020 | 18337 | 0.050 |
Why?
|
Antibiotics, Antineoplastic | 4 | 1997 | 686 | 0.050 |
Why?
|
Sex Distribution | 1 | 2006 | 2304 | 0.050 |
Why?
|
Propensity Score | 2 | 2020 | 1747 | 0.050 |
Why?
|
Solitary Fibrous Tumor, Pleural | 1 | 2020 | 27 | 0.050 |
Why?
|
Mitomycin | 2 | 1998 | 256 | 0.050 |
Why?
|
Mastectomy | 2 | 2012 | 1752 | 0.050 |
Why?
|
Mitotic Index | 1 | 2020 | 173 | 0.050 |
Why?
|
Furans | 1 | 2021 | 186 | 0.050 |
Why?
|
Ketones | 1 | 2021 | 184 | 0.050 |
Why?
|
Retreatment | 1 | 2021 | 603 | 0.040 |
Why?
|
Drug Interactions | 1 | 2004 | 1448 | 0.040 |
Why?
|
Child | 4 | 2021 | 75163 | 0.040 |
Why?
|
Hemoperitoneum | 1 | 1999 | 38 | 0.040 |
Why?
|
Biliary Fistula | 1 | 1999 | 36 | 0.040 |
Why?
|
Skin | 1 | 2012 | 4311 | 0.040 |
Why?
|
Registries | 1 | 2015 | 7910 | 0.040 |
Why?
|
Patient Advocacy | 1 | 2021 | 350 | 0.040 |
Why?
|
Vindesine | 1 | 1998 | 12 | 0.040 |
Why?
|
Evaluation Studies as Topic | 3 | 2016 | 1700 | 0.040 |
Why?
|
Vincristine | 3 | 1997 | 1049 | 0.040 |
Why?
|
Positron-Emission Tomography | 1 | 2015 | 6180 | 0.040 |
Why?
|
Polymerase Chain Reaction | 2 | 2007 | 6225 | 0.040 |
Why?
|
Disease Management | 2 | 2021 | 2442 | 0.040 |
Why?
|
Leucovorin | 2 | 1997 | 623 | 0.040 |
Why?
|
Genes, bcl-2 | 1 | 1998 | 124 | 0.040 |
Why?
|
Doxorubicin | 5 | 1997 | 2224 | 0.040 |
Why?
|
Carcinoma, Ductal, Breast | 2 | 2012 | 1096 | 0.040 |
Why?
|
Radiotherapy, High-Energy | 1 | 1999 | 230 | 0.040 |
Why?
|
Drug Tolerance | 2 | 1996 | 378 | 0.040 |
Why?
|
Karnofsky Performance Status | 1 | 1998 | 175 | 0.040 |
Why?
|
Respiratory Insufficiency | 1 | 2006 | 1167 | 0.040 |
Why?
|
Carboplatin | 2 | 1998 | 798 | 0.040 |
Why?
|
Genetic Predisposition to Disease | 1 | 2019 | 17328 | 0.040 |
Why?
|
Acute Coronary Syndrome | 1 | 2011 | 2274 | 0.040 |
Why?
|
Cyclin D1 | 1 | 1999 | 464 | 0.040 |
Why?
|
Recombinant Proteins | 6 | 1997 | 6669 | 0.040 |
Why?
|
North America | 1 | 2020 | 1205 | 0.040 |
Why?
|
Multivariate Analysis | 4 | 2017 | 12244 | 0.040 |
Why?
|
Histocompatibility Testing | 1 | 1999 | 749 | 0.040 |
Why?
|
Azathioprine | 1 | 1998 | 352 | 0.040 |
Why?
|
Isomerism | 1 | 1996 | 203 | 0.040 |
Why?
|
Remission Induction | 3 | 1996 | 2366 | 0.040 |
Why?
|
Angina Pectoris | 1 | 2021 | 1001 | 0.040 |
Why?
|
Myocardial Revascularization | 1 | 2021 | 839 | 0.040 |
Why?
|
Quality of Life | 3 | 2023 | 12113 | 0.040 |
Why?
|
Child, Preschool | 1 | 2019 | 40429 | 0.040 |
Why?
|
Peritonitis | 1 | 1999 | 365 | 0.040 |
Why?
|
Critical Pathways | 1 | 2020 | 464 | 0.040 |
Why?
|
Death | 1 | 2021 | 642 | 0.040 |
Why?
|
Estrogens, Non-Steroidal | 1 | 1996 | 54 | 0.040 |
Why?
|
Immunohistochemistry | 4 | 2019 | 11486 | 0.040 |
Why?
|
Thymidine | 1 | 1996 | 326 | 0.040 |
Why?
|
Hernia, Inguinal | 1 | 1998 | 200 | 0.040 |
Why?
|
Lipopolysaccharides | 1 | 2023 | 2195 | 0.030 |
Why?
|
Adrenalectomy | 1 | 2017 | 339 | 0.030 |
Why?
|
Antineoplastic Agents, Alkylating | 2 | 1996 | 617 | 0.030 |
Why?
|
DNA-Binding Proteins | 1 | 2013 | 9714 | 0.030 |
Why?
|
Abdominal Neoplasms | 1 | 1997 | 289 | 0.030 |
Why?
|
Leukocyte Count | 2 | 1997 | 1614 | 0.030 |
Why?
|
Administration, Oral | 2 | 2007 | 3907 | 0.030 |
Why?
|
Thoracic Neoplasms | 1 | 1997 | 259 | 0.030 |
Why?
|
Sarcoma, Synovial | 1 | 1996 | 161 | 0.030 |
Why?
|
Reactive Oxygen Species | 1 | 2022 | 2078 | 0.030 |
Why?
|
Tacrolimus | 1 | 1998 | 724 | 0.030 |
Why?
|
Anthracyclines | 1 | 1996 | 274 | 0.030 |
Why?
|
Immunization, Passive | 1 | 1997 | 625 | 0.030 |
Why?
|
Radiography, Thoracic | 1 | 2001 | 1257 | 0.030 |
Why?
|
Length of Stay | 2 | 2020 | 6230 | 0.030 |
Why?
|
Europe | 1 | 2020 | 3293 | 0.030 |
Why?
|
Radiodermatitis | 1 | 2013 | 60 | 0.030 |
Why?
|
Receptor, IGF Type 1 | 1 | 1996 | 396 | 0.030 |
Why?
|
Ventricular Dysfunction, Left | 1 | 2004 | 1997 | 0.030 |
Why?
|
Respiratory Function Tests | 1 | 1998 | 1618 | 0.030 |
Why?
|
Genital Neoplasms, Female | 1 | 2019 | 508 | 0.030 |
Why?
|
Morbidity | 1 | 1999 | 1729 | 0.030 |
Why?
|
Osteosarcoma | 1 | 2019 | 872 | 0.030 |
Why?
|
Rib Fractures | 1 | 2014 | 115 | 0.030 |
Why?
|
Esophagitis | 1 | 2013 | 146 | 0.030 |
Why?
|
Feasibility Studies | 3 | 1996 | 4942 | 0.030 |
Why?
|
Colectomy | 1 | 2017 | 664 | 0.030 |
Why?
|
Mutation | 2 | 2014 | 29645 | 0.030 |
Why?
|
Databases, Factual | 2 | 2020 | 7681 | 0.030 |
Why?
|
Hepatitis B | 1 | 1997 | 660 | 0.030 |
Why?
|
Prevalence | 2 | 2019 | 14951 | 0.030 |
Why?
|
Radioisotopes | 1 | 2013 | 502 | 0.030 |
Why?
|
Emergency Service, Hospital | 1 | 2011 | 7400 | 0.030 |
Why?
|
United States | 4 | 2020 | 68433 | 0.030 |
Why?
|
Focus Groups | 1 | 2016 | 1285 | 0.030 |
Why?
|
Biopsy | 2 | 2021 | 6725 | 0.020 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2006 | 3891 | 0.020 |
Why?
|
Chi-Square Distribution | 2 | 2013 | 3510 | 0.020 |
Why?
|
Mitosis | 1 | 1996 | 1246 | 0.020 |
Why?
|
Home Care Services | 1 | 1996 | 587 | 0.020 |
Why?
|
Neck Dissection | 1 | 2012 | 192 | 0.020 |
Why?
|
Asthenia | 1 | 1969 | 16 | 0.020 |
Why?
|
Liver Cirrhosis | 2 | 1997 | 1788 | 0.020 |
Why?
|
Lorazepam | 1 | 1990 | 143 | 0.020 |
Why?
|
Lymphoma | 1 | 2019 | 1859 | 0.020 |
Why?
|
Postoperative Period | 1 | 2015 | 1835 | 0.020 |
Why?
|
Lung | 3 | 2017 | 9812 | 0.020 |
Why?
|
Adjustment Disorders | 1 | 1969 | 70 | 0.020 |
Why?
|
Safety | 1 | 2014 | 1186 | 0.020 |
Why?
|
Pyridoxine | 1 | 1969 | 102 | 0.020 |
Why?
|
Perioperative Care | 1 | 2017 | 1057 | 0.020 |
Why?
|
Diarrhea | 1 | 1996 | 1334 | 0.020 |
Why?
|
Protein Kinase Inhibitors | 1 | 2006 | 5458 | 0.020 |
Why?
|
Antigens, Tumor-Associated, Carbohydrate | 1 | 1990 | 134 | 0.020 |
Why?
|
Lung Diseases | 2 | 1998 | 1905 | 0.020 |
Why?
|
Radiometry | 1 | 2014 | 800 | 0.020 |
Why?
|
Adrenal Gland Neoplasms | 1 | 2014 | 737 | 0.020 |
Why?
|
Virus Replication | 1 | 1997 | 2546 | 0.020 |
Why?
|
Immunosuppressive Agents | 2 | 1999 | 4109 | 0.020 |
Why?
|
Survival | 1 | 2008 | 160 | 0.020 |
Why?
|
Reoperation | 2 | 2013 | 4156 | 0.020 |
Why?
|
Endpoint Determination | 1 | 2011 | 601 | 0.020 |
Why?
|
Pilot Projects | 3 | 2016 | 8099 | 0.020 |
Why?
|
Gadolinium | 1 | 2013 | 935 | 0.020 |
Why?
|
Carcinoma, Neuroendocrine | 1 | 2012 | 320 | 0.020 |
Why?
|
Mortality | 1 | 2019 | 2825 | 0.020 |
Why?
|
Molecular Targeted Therapy | 1 | 2019 | 2759 | 0.020 |
Why?
|
Keratin-19 | 1 | 2007 | 32 | 0.020 |
Why?
|
Keratin-7 | 1 | 2007 | 57 | 0.020 |
Why?
|
Vomiting | 1 | 1990 | 613 | 0.020 |
Why?
|
Antifibrinolytic Agents | 1 | 2010 | 248 | 0.020 |
Why?
|
Porphyrins | 1 | 1969 | 347 | 0.020 |
Why?
|
Computer Simulation | 1 | 2001 | 6158 | 0.020 |
Why?
|
Sex Characteristics | 1 | 1997 | 2547 | 0.020 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2014 | 1668 | 0.020 |
Why?
|
Interleukin-2 | 1 | 1994 | 1896 | 0.020 |
Why?
|
Interferon-alpha | 1 | 1991 | 894 | 0.020 |
Why?
|
Bone Marrow | 1 | 1997 | 2909 | 0.020 |
Why?
|
Laparoscopy | 1 | 1998 | 2030 | 0.020 |
Why?
|
Vitamin B 12 | 1 | 1969 | 521 | 0.020 |
Why?
|
Hematologic Diseases | 1 | 1969 | 492 | 0.020 |
Why?
|
DNA Mutational Analysis | 1 | 2014 | 4249 | 0.020 |
Why?
|
Hepatitis C, Chronic | 1 | 1994 | 1013 | 0.020 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 1 | 2012 | 933 | 0.020 |
Why?
|
Severity of Illness Index | 2 | 2014 | 15454 | 0.020 |
Why?
|
Carcinoma, Hepatocellular | 1 | 1997 | 2163 | 0.020 |
Why?
|
Liver Neoplasms | 2 | 1997 | 4171 | 0.020 |
Why?
|
Hypotension | 1 | 1969 | 835 | 0.020 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2001 | 8909 | 0.010 |
Why?
|
DNA Repair | 1 | 2013 | 2045 | 0.010 |
Why?
|
Aortic Aneurysm, Thoracic | 1 | 2010 | 666 | 0.010 |
Why?
|
Premenopause | 1 | 2007 | 1026 | 0.010 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2011 | 9589 | 0.010 |
Why?
|
Ultrasonography | 1 | 2016 | 5894 | 0.010 |
Why?
|
Mastectomy, Segmental | 1 | 2007 | 947 | 0.010 |
Why?
|
Probability | 1 | 2007 | 2485 | 0.010 |
Why?
|
Leukemia | 1 | 1969 | 1495 | 0.010 |
Why?
|
Carcinoma, Squamous Cell | 2 | 2014 | 3948 | 0.010 |
Why?
|
Cell Division | 2 | 1999 | 4605 | 0.010 |
Why?
|
Drug Therapy, Combination | 3 | 1998 | 6457 | 0.010 |
Why?
|
Diagnosis, Differential | 1 | 2016 | 12937 | 0.010 |
Why?
|
Recurrence | 3 | 1998 | 8216 | 0.010 |
Why?
|
Adrenal Cortex Hormones | 1 | 1969 | 1829 | 0.010 |
Why?
|
Aortic Aneurysm, Abdominal | 1 | 2010 | 1178 | 0.010 |
Why?
|
Genotype | 1 | 2014 | 12882 | 0.010 |
Why?
|
Myocardial Infarction | 1 | 2021 | 11531 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2017 | 21575 | 0.010 |
Why?
|
Ploidies | 1 | 1999 | 280 | 0.010 |
Why?
|
Postmenopause | 1 | 2007 | 2440 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2016 | 19620 | 0.010 |
Why?
|
Risk | 1 | 2011 | 9697 | 0.010 |
Why?
|
Quality Control | 1 | 2001 | 847 | 0.010 |
Why?
|
Cause of Death | 2 | 1999 | 3557 | 0.010 |
Why?
|
Actuarial Analysis | 1 | 1997 | 377 | 0.010 |
Why?
|
Tissue Distribution | 1 | 2001 | 2360 | 0.010 |
Why?
|
Least-Squares Analysis | 1 | 1997 | 378 | 0.010 |
Why?
|
SEER Program | 1 | 2002 | 1513 | 0.010 |
Why?
|
Antidotes | 1 | 1997 | 137 | 0.010 |
Why?
|
Prostatic Neoplasms | 1 | 2019 | 10879 | 0.010 |
Why?
|
Hepatitis B Surface Antigens | 1 | 1997 | 292 | 0.010 |
Why?
|
Tritium | 1 | 1996 | 771 | 0.010 |
Why?
|
Mitomycins | 1 | 1995 | 46 | 0.010 |
Why?
|
Thoracotomy | 1 | 1997 | 364 | 0.010 |
Why?
|
Graft Rejection | 2 | 1999 | 4376 | 0.010 |
Why?
|
Stroke Volume | 2 | 1997 | 4753 | 0.010 |
Why?
|
Thorax | 1 | 1997 | 533 | 0.010 |
Why?
|
Hepatitis C Antibodies | 1 | 1994 | 145 | 0.010 |
Why?
|
Chromosome Aberrations | 1 | 2000 | 1813 | 0.010 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2013 | 15404 | 0.010 |
Why?
|
Hepatitis B virus | 1 | 1997 | 485 | 0.010 |
Why?
|
Immunoglobulins | 1 | 1997 | 897 | 0.010 |
Why?
|
Mucous Membrane | 1 | 1996 | 667 | 0.010 |
Why?
|
Phantoms, Imaging | 1 | 2001 | 2471 | 0.010 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 1996 | 639 | 0.010 |
Why?
|
Survivors | 1 | 2002 | 2219 | 0.010 |
Why?
|
Interferons | 1 | 1995 | 687 | 0.010 |
Why?
|
Peripheral Nervous System Diseases | 1 | 1996 | 701 | 0.010 |
Why?
|
DNA, Viral | 1 | 1997 | 2270 | 0.010 |
Why?
|
Drug Evaluation | 1 | 1991 | 649 | 0.010 |
Why?
|
Leukopenia | 1 | 1990 | 210 | 0.010 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 1 | 1996 | 1391 | 0.010 |
Why?
|
Injections, Intramuscular | 1 | 1990 | 552 | 0.010 |
Why?
|
Fever | 1 | 1996 | 1561 | 0.010 |
Why?
|
Biliary Tract Diseases | 1 | 1969 | 159 | 0.010 |
Why?
|
Flow Cytometry | 1 | 1999 | 5970 | 0.010 |
Why?
|
Mediastinal Neoplasms | 1 | 1991 | 427 | 0.000 |
Why?
|
Graft Survival | 1 | 1998 | 3726 | 0.000 |
Why?
|
Embolization, Therapeutic | 1 | 1997 | 1336 | 0.000 |
Why?
|
Platelet Count | 1 | 1990 | 785 | 0.000 |
Why?
|
Urologic Diseases | 1 | 1969 | 240 | 0.000 |
Why?
|
Drug Synergism | 1 | 1991 | 1799 | 0.000 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 1994 | 3877 | 0.000 |
Why?
|
Surgical Procedures, Operative | 1 | 1998 | 1875 | 0.000 |
Why?
|
Antibodies | 1 | 1994 | 2418 | 0.000 |
Why?
|
RNA, Viral | 1 | 1994 | 2894 | 0.000 |
Why?
|
Ovarian Neoplasms | 1 | 2002 | 4755 | 0.000 |
Why?
|
Ventricular Function, Left | 1 | 1996 | 3498 | 0.000 |
Why?
|
Melanoma | 1 | 2002 | 5357 | 0.000 |
Why?
|
Pain | 1 | 1998 | 4846 | 0.000 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 1994 | 4409 | 0.000 |
Why?
|
Colorectal Neoplasms | 1 | 2002 | 6672 | 0.000 |
Why?
|
Apoptosis | 1 | 1998 | 9754 | 0.000 |
Why?
|
Drug Resistance, Neoplasm | 1 | 1996 | 5169 | 0.000 |
Why?
|
Double-Blind Method | 1 | 1990 | 11885 | 0.000 |
Why?
|
Adenocarcinoma | 1 | 1991 | 6351 | 0.000 |
Why?
|
Antibodies, Monoclonal | 1 | 1990 | 9248 | 0.000 |
Why?
|